Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25675415 | 0.77 | CDC7 (0.34) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL29143502 | 0.77 | TYMP (0.39) | — | |
| SCHEMBL1586348 | 0.72 | CYP1A2 (0.39) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL5844067 | 0.72 | PDK2 (0.37) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL15201046 | 0.71 | CYP1A2 (0.36) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL20349181 | 0.71 | — | — | |
| SCHEMBL857094 | 0.71 | CYP1A2 (0.36) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL25675417 | 0.71 | TLR8 (0.31) | KDM4E | |
| SCHEMBL439985 | 0.71 | PDE10A (0.39) | KDM4E | |
| SCHEMBL30888304 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2012-03-15 | — | — | US | disclosed |
| US-8076350-B2 | 3H-(4's)-1'-azaspiro[benzofuran-2,4']-tricyclo[3.3.1.13,7]decane; for therapy of memory disorder, cognitive disorder, neurodegeneration, and neurodevelopmental disorder; attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment | ABBOTT LABORATORIES (US) | 2011-12-13 | — | — | US | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065219-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CYP1A2 92/4885CYP2D6 45/4885CYP2C9 143/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CYP1A2 95/4885CYP2D6 47/4885CYP2C9 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.